Grade: Pharmaceutical Grade

Factory Location: QUANZHOU

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Baloxavir marboxil is a prodrug of S-033447. S-033447 is a small molecule inhibitor of the cap-dependent endonuclease of influenza A and B viruses, which developed by Shionogi & Roche.

Indication: Influenza

All the products under the patent are only for R&D use.

Patent from Shionogi & Roche, expiry date(The U.S):Sep.21, 2031.